{
  "abstract": "The integration of pharmacotherapy into abstinence-oriented recovery communities has historically been met with friction. However, a new dynamic may be emerging with the rise of GLP-1 agonists (e.g., semaglutide). While robust clinical trial data for GLP-1s regarding the treatment of substance use disorders remains unclear, these new medications are being adopted off-label by innovators in abstinence-oriented treatment facilities and selectively within the 12-step recovery community. This commentary provides an analysis of this phenomenon through the application of Rogers’ Diffusion of Innovations theory. We argue that unlike previous medications which faced medication stigma for their psychoactive properties, it may be possible that GLP-1s are being met with less resistance from the recovery community because their mechanism of action is culturally congruent with the 12-step goal of relieving the mental obsession of addiction. We posit that this new phenomenon represents a practice-based evidence signal that deserves attention; perhaps the 12-step recovery community is not as anti-medication as once thought.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "name": "Wayne Kepner"
    },
    {
      "name": "Steven Klein"
    },
    {
      "name": "Keith Humphreys"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ajf3nze0772w5.bib",
  "cited_by": 0,
  "doi": "10.31234/osf.io/jvqdz_v1",
  "fulltext_url": null,
  "id": "ajf3nze0772w5",
  "issns": [],
  "landing_url": "https://osf.io/preprints/psyarxiv/jvqdz_v1/",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "bepress",
      "Clinical Psychology"
    ],
    [
      "bepress",
      "Psychiatry"
    ],
    [
      "bepress",
      "Social and Behavioral Sciences"
    ],
    [
      "bepress",
      "Substance Abuse and Addiction"
    ],
    [
      "openalex",
      "2713|Substance Abuse Treatment and Outcomes"
    ]
  ],
  "openalex": "W7223342825",
  "pdf_url": "https://osf.io/jvqdz/download",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ajf3nze0772w5.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:20Z",
      "native_id": "jvqdz",
      "source": "osf",
      "url": "https://osf.io/preprints/psyarxiv/jvqdz_v1/"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "bepress:Clinical Psychology",
      "subfield": "psychiatry"
    }
  ],
  "title": "Will members of 12-step recovery groups oppose the use of GLP-1 agonists for addiction?",
  "title_text": "Will members of 12-step recovery groups oppose the use of GLP-1 agonists for addiction?",
  "type": "preprint",
  "updated_at": "2026-10-30T12:19:20Z",
  "url": "https://research.draconitic.com/paper/ajf3nze0772w5",
  "venue": "PsyArXiv",
  "versions": []
}